Can Novel Anticoagulants Reduce Thrombosis Without Increasing Bleeding – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Surasak Wichaiyo, published in Journal of Thrombosis and Haemostasis, adding:
“Pharmacology of anticoagulants: from heparin to novel target-specific agents.
This review delineates the pharmacology of currently available anticoagulants (heparins, warfarin, and direct oral anticoagulants) alongside investigational agents.
Factor XI and factor XII inhibitors emerge as targets that may uncouple antithrombotic efficacy from bleeding risk, with several FXI inhibitors now in phase II and III trials.”
Title: Pharmacology of anticoagulants: from heparin to novel target-specific agents
Authors: Surasak Wichaiyo
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 27, 2026, 16:28Rose Agor: Celebrating Two New Publications in Haematology Research
-
Oct 27, 2026, 16:21Pregnancy and Thrombosis-What Clinicians Need to Know – World Thrombosis Day
-
Oct 27, 2026, 16:13Lesley Van Wyk: DIC vs TTP vs HUS – The Key Diagnostic Clues
-
Oct 27, 2026, 16:02Ahmad G. Alzahrani: AF and Vascular Risk Factors – Should We Add Antiplatelet Therapy?
-
Oct 27, 2026, 16:02Iron Deficiency and Thrombocytosis: How Iron Availability Shapes Hematopoietic Lineage Decisions
-
Oct 27, 2026, 15:46Christiane Berger-Schaffitzel: New PhD Project Explores Snake Venom and Haemostasis
-
Oct 27, 2026, 13:51Muhammed Hajmusa: ESMO 2026 Highlights the Challenge of Anticoagulation in ROS1-Positive Lung Cancer
-
Oct 27, 2026, 13:39Luca Galassi: Retrieved Venous Thrombi as a Tool for Predicting Post-Thrombotic Syndrome
-
Oct 27, 2026, 11:43Tareq Abadl: Hidden Interferences Behind Unexpected Laboratory Results